98 related articles for article (PubMed ID: 34859824)
1. The Value of Immunohistochemical Methods and Preoperative Magnetic Resonance Imaging Findings in Diagnosis of IDH1 Mutant Glioblastomas.
Kiraz U; Vural C; Turan G; Alparslan B; Dervisoglu E
Turk Neurosurg; 2022; 32(2):228-236. PubMed ID: 34859824
[TBL] [Abstract][Full Text] [Related]
2. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
4. Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma.
Pyo JS; Kim NY; Kim RH; Kang G
Brain Tumor Pathol; 2016 Oct; 33(4):248-254. PubMed ID: 27638721
[TBL] [Abstract][Full Text] [Related]
5. IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.
Urbanovska I; Megova MH; Dwight Z; Kalita O; Uvirova M; Simova J; Tuckova L; Buzrla P; Palecek T; Hajduch M; Dvorackova J; Drabek J
Pathol Oncol Res; 2019 Jul; 25(3):971-978. PubMed ID: 29556922
[TBL] [Abstract][Full Text] [Related]
6. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas.
Malueka RG; Theresia E; Fitria F; Argo IW; Donurizki AD; Shaleh S; Innayah MR; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA; Dwianingsih EK
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3229-3234. PubMed ID: 33247679
[TBL] [Abstract][Full Text] [Related]
8. Increased
Koyasu S; Shimizu Y; Morinibu A; Saga T; Nakamoto Y; Togashi K; Harada H
J Neurooncol; 2019 Dec; 145(3):441-447. PubMed ID: 31667733
[TBL] [Abstract][Full Text] [Related]
9. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
12. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
13. Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
Price SJ; Allinson K; Liu H; Boonzaier NR; Yan JL; Lupson VC; Larkin TJ
Radiology; 2017 Apr; 283(1):215-221. PubMed ID: 27849434
[TBL] [Abstract][Full Text] [Related]
14. Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.
Ishi Y; Yamaguchi S; Okamoto M; Sawaya R; Endo S; Motegi H; Terasaka S; Tanei ZI; Hatanaka KC; Tanaka S; Fujimura M
Brain Tumor Pathol; 2022 Jul; 39(3):162-170. PubMed ID: 35362874
[TBL] [Abstract][Full Text] [Related]
15. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
[TBL] [Abstract][Full Text] [Related]
17. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
[TBL] [Abstract][Full Text] [Related]
18. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
19. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
20. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]